ArticleMedComm2026
Global Burden of Diseases Attributable to Early Maturation in 2021.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early maturation poses a considerable health challenge worldwide. We aim to quantify the global disease burden attributable to early maturation in 2021. We calculated sex-specific and region-specific population attributable fractions (PAFs) of diseases through meta-analysis and Mendelian randomization. The age-standardized incidence rate (ASIR) with 95% uncertainty intervals (UIs) of these diseases, stratified by sex, age, and development status were estimated using the Global Burden of Diseases database. Asthma, Type 2 diabetes, ischemic heart disease, stroke, uterine cancer, testicular cancer, and depression was causally related with early maturation, with PAF ranging from 7.7% for uterine cancer to 0.8% for Type 2 diabetes. About 11.2 million new attributable cases occurs, with an ASIR of 210.1 (95% UI 155.1-280.7) cases per 100,000, with higher PAF in females (3.4%) than in males (2.3%). The ASIR was highest in North America (405.5, 309.0-526.3 cases per 100,000) and lowest in East Asia and the Pacific (120.8, 89.6-160.3 cases per 100,000). More developed regions showed 1.4 times higher incidence burden (ASIR 268.5, 199.6-356.6 cases per 100,000) than less developed regions. Therefore, regional adoption of effective public health interventions to alleviate early maturation, notably for females in more developed regions, has enormous potential to reduce worldwide disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.